MedTrace Logo

Effects of T-bet B Cells in Persistent Virus Control After Discontinuance of NAs in CHB Patients

NCT06029634 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2023-09-08

No results posted yet for this study

Summary

The immune mechanism of the nucleos(t)ide analogs (NAs) in inhibiting HBV replication effectively while having a low sustained virus control rate after drug withdrawal is unclear. B cell immunity and antibody response are the keys to prevent HBV reinfection and keep the virus under control. T-bet+ B, which can be regulated by IL-21, is a newly discovered major effector B cell in protection of pathogens and it is a main subtype of HBsAg-specific B cells. Thus, we suspect that T-bet+ B may play a role in ongoing controlling of the virus after withdraw of NAs in CHB patient. Based on our previous studies on CHB immunity, we use the RNAseq analyse, flow cytometry, and Elispot assay to analyze the frequency, function, and phenotype of B cells in CHB patients with different profiles after withdraw of NAs.

Conditions

  • Chronic HBV Infection
  • Drug Withdrawal

Interventions

DIAGNOSTIC_TEST

T-bet B cell

The frequency, function, and phenotype of T-bet B cells was tested

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Xuesong Liang, DR · Chaihai hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2023-08-10
Completion
2023-08-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06029634 on ClinicalTrials.gov